Clinical Trial Update: Ex Vivo Gene Therapy Clinical Trial for RDEB Using Genetically Corrected Autologous Skin Equivalent Grafts [Phase 1, Phase 2]

View source ↗

Summary

This update covers an ex vivo gene therapy trial for recessive dystrophic epidermolysis bullosa using genetically corrected autologous skin equivalents, current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa Recessive Dystrophic

Drugs mentioned

• Genetically corrected autologous epidermal grafts (skin equivalents)

Snippet

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France | Conditions: Epidermolysis Bullosa Dystrophica, Recessive | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING